In-article:

Valneva on the rise, the European Medicines Agency authorizes the marketing of its vaccine


After the positive opinion issued in the middle of last week by the Committee for Medicinal Products for Human Use, the European Medicines Agency authorized, on Friday evening, the marketing of Valneva’s candidate vaccine against Covid.

VALNEVA

Valneva on the rise, the European Medicines Agency authorizes the marketing of its vaccine | Photo credits: Valneva

After the positive opinion issued in the middle of last week by the Committee for Medicinal Products for Human Use (CHMP), Valneva took a new step on Friday, with the marketing authorization of its vaccine against Covid by the Agency. European Medicines (EMA). The action gained just under 5% on Monday morning, at 13.25 euros, while continuing to lose 45% since the start of the year.

Since we started working on VLA2001, we have constantly received messages from Europeans who are waiting for more traditional vaccine technology. Now that we have received this marketing authorization, we hope that the Commission and its Member States will place orders that reflect this request.the biotech said in a statement, 15% of Europeans over the age of 18 are not yet vaccinated and we believe that the availability of our inactivated vaccine could increase vaccination coverage and have a significant impact on public health. »

A crucial need for orders

Still, these positive opinions and marketing authorization must be followed by orders. After the British government terminated its supply contract, the European Commission indicated its intention to do the same.

In mid-June, Valneva reached an out-of-court settlement with London following the British government’s termination of a contract for the supply of 100 million doses of its vaccine candidate. He had canceled this order in September, claiming that the French laboratory had failed in its obligations, which Valneva had disputed.

In mid-May, the biotech had warned that the group could have to reassess its financial forecasts after the European Commission informed it of its intention to end the advance purchase agreement for its vaccine. On June 13, the stock had lost a quarter of its value as the company’s management expressed concern that the supply agreement with the European Commission was threatened due to a lack of sufficient volumes, which could jeopardize this program.





Source link -91